On December 31, 2024, a San Diego police officer rescued a non-breathing one-year-old infant in Point Loma. Around 1:35 p.m., a woman frantically called police about a baby not breathing in the 1100 block of Sunset Cliffs Boulevard.
The 911 dispatcher provided CPR instructions over the phone. Upon arrival, Officer Warner assisted in resuscitating the child. The infant was transported to a local hospital and is expected to make a full recovery.
This incident highlights the critical role of prompt emergency response and effective dispatcher guidance in life-threatening situations.
Earlier this week, Moderna paused its mRNA RSV (Respiratory Syncytial Virus) vaccine trial for children after five infants were hospitalized with severe respiratory complications. This decision follows similar safety concerns recently acknowledged by the FDA, which halted enrollment in related trials for children under two years old.
The development came to light during Thursday’s FDA Vaccines and Related Biological Products Advisory Committee (VRBPAC) meeting. According to Fierce Pharma, panelists grappled with the safety implications of Moderna’s findings. Henry Bernstein, a professor of pediatrics at Hofstra/Northwell, noted, “This all seems like an incredible conundrum with lots of unanswered questions remaining—lots to still learn.”
The paused trial, labeled mRNA-1365-P101, was designed to evaluate the safety, tolerability, and immunogenicity of two mRNA-based vaccines, mRNA-1345 and mRNA-1365. These vaccines were intended to protect infants and toddlers against RSV.
The FDA briefing document explained, “A potential safety signal for RSV sLRTI (severe lower respiratory tract infection) was identified, and as additional information accrued, an imbalance in cases of RSV sLRTI was noted, with more cases identified in the vaccine groups compared with the control group. This raised a concern for possible VAERD (vaccine-associated enhanced respiratory disease).”
